| ObjectiveThrough comparing the joint scheme of vitamin D combined loratadine and fluticasone propionate nasal spray with two solutions of loratadine and fluticasone propionate nasal spray in curative effect of allergic rhinitis, clinicians provide a better solution for clinical treatment of allergic rhinitis and promote the development of clinical medicine.MethodsA total of 80 coal miners with allergic rhinitis in the Department of ENT during the period of January in 2014 to June in 2015 were adopted for experiments. All patients were told this study related cases and signed the informed consents. The selected patients were randomly divided into experimental group and control group, 40 cases in each group. The experimental group of patients were given orally loratadine(trade name: Mr Snow, manufacturers: Yangtze river pharmaceutical, specifications: 75 mg/tablet) 75 mg,once daily, taken before dinner; Fluticasone propionate nasal spray(trade name: auxiliary Shu Liang, origin: Spain, specifications: 50 ug/spray) 10 ug, 2 times a day; Oral vitamin D drops(producer: sinopharm star shark pharmaceutical(xiamen) :specifications: 400units/grain) 800 units, 1 times a day, on an empty stomach. Control group patients were given orally loratadine(trade name: Mr Snow, manufacturers: Yangtze river pharmaceutical, specifications: 75 mg/tablet) 75 mg, once daily, taken before dinner;Fluticasone propionate nasal spray(trade name: auxiliary Shu Liang, origin: Spain,specifications: 50 ug/spray) 10 ug, 2 times a day. By comparing the symptoms, signs, curative effect, the serum[25(OH)D3]level and the recurrence rate, the difference of the treatment with two groups was analysed. There were no statistical differences in gender,age, duration, and degree of the disease(symptoms, score and the detection of serum[25(OH)D3](P > 0.05), the data were balanced and comparable. Selected subjects who excluding vitamin D related diseases, have not received treatment of AR within one month.ResultsA total of 80 cases in the experimental results were complete, control group 40 cases, 40 cases in treatment group. Before the experiment, age, course of the disease, the degreeof the disease such as general data carried on the analysis comparison. After statistics analysis, the results showed that there were no statistically significant difference(P < 0.05), the data is balanced.The treatment of patients with clinical curative effect: all the total course of 8weeks, 8 weeks after the drug was stopped to observe the clinical efficacy of two groups of patients, and compare. The experimental group taked effect for 18 cases(45%),effective for 21 cases(52.5%), 1 case had no effect(2.5%), the total effective rate was97.5%; The control group taked effect for 13 cases(32.5%), effective for 20 cases(50%),invalid have 7 cases(17.5%), effective rate was 82.5%. Comparative differences between the two groups have statistical significance(P< 0.05, X2=5.00), i.e., 8 weeks after treatment, the cure rate of vitamin D combined loratadine and fluticasone propionate nasal spray were significantly better than the cure rate of loratadine and fluticasone propionate.Signs and symptoms of quantitative comparison: in 8 weeks after treatment on two groups of patients with symptoms and signs of quantitative score comparison. Results showed that the experimental group of patients with symptoms(1.32 ± 0.13) for quantitative score points,(1.24±0.32) for signs score points, while the control group of patients with symptoms score(2.12±0.43) for quantitative score points,(2.04±0.38) for signs score points, the comparison between groups was statistically difference(P < 0.05),suggesting that after 8 weeks of treatment, vitamin D combined loratadine and fluticasone propionate nasal spray the joint scheme can effectively improve the signs and symptoms of patients with allergic rhinitis, and loratadine joint fluticasone propionate two scheme of improvement is not obvious.The serum 25(OH)D3 level in two groups were compared. The serum 25(OH)D3level of the control group before treatment was(24.87±2.67)ng / ml,and The serum25(OH)D3 level of the experimental group before treatment was(24.00±2.38)ng /ml.There was no significant difference(P>0.05).The serum 25(OH)D3 level of the control group after treatment was(29.15±2.78)ng/ml, and The serum 25(OH)D3 level of the experimental group before treatment was(33.14±3.32)ng / ml.There was significant difference(P<0.05).The recurrence rate in two groups were compared. Two groups of patients in six months after the treatment were under investigation. The results showed that the recurrence rate of the control group was 35 % while the recurrence rate of the experimental group was 50 %.There was significant difference(P<0.05).ConclusionAllergic rhinitis is a kind of recurrent stronger autoimmune disease of nasal cavity and the coal miners due to work and the environmental impact are more easier to suffer from allergic rhinitis. Current clinical treatment effect is not optimistic, to control as the core more. In addition, the process of treatment need to take medicine for a long time,making it easier for the patient to a drug dependent, and the recurrence rate is extremely high. As a result, patients often fail to adhere the treatment, lead to illness, and even affect the patient’s life and work. And participate in regulating the immune system,vitamin D may play an important role in immune-mediated disease, at the same time can improve the Allergic rhinitis, such as autoimmune disease condition, and can effectively improve the signs and symptoms of patients with rhinitis, improve patient quality of life. |
PDF Full Text Request